Pediatric COVID-19 in Argentina: a comprehensive analysis of disease and economic burden through official data and a systematic literature review
- PMID: 38606369
- PMCID: PMC11007211
- DOI: 10.3389/fped.2024.1352260
Pediatric COVID-19 in Argentina: a comprehensive analysis of disease and economic burden through official data and a systematic literature review
Abstract
Background: Limited data are available on the clinical impact and economic burden of COVID-19 in the pediatric population in Argentina. We aimed to estimate the disease and economic burden of COVID-19 on children and adolescents.
Methods: We analyzed official national databases and conducted a supplemental systematic review of the published literature with meta-analysis in children aged 0-18. The period of interest was from March 2020 to August 2021, before the introduction of vaccination in this age group as a national strategic plan. In addition, we used a cost of illness analysis to estimate the direct medical costs associated with COVID-19. All costs are reported in US dollars 2023.
Results: A total of 450,503 confirmed COVID-19 cases and 180 multisystem inflammatory syndrome (MIS-C) were reported in Argentina in the study period. Fourteen observational clinical studies were identified. The meta-analyses of severity level from hospital patients showed that according to different studies 15%-28% of cases were asymptomatic, 68%-88% were mild or moderate, and 3%-10% were severe or critical. About 28% of children had an underlying disease. In addition, the estimated economic burden associated with COVID-19 was 80 million dollars and 4 million dollars corresponded to MISC.
Conclusion: Significant impact of COVID-19 on the healthcare system and substantial economic implications for the pediatric population in Argentina were identified. The findings should help policymakers to make informed decisions and allocate resources effectively.
Keywords: Argentina; disease burden; economic burden; meta-analysis; multisystem inflammatory syndrome; pediatric COVID-19; systematic review.
© 2024 Bardach, Ruvinsky, Moreno, Perelli, Kyaw, Spinardi, Mendoza, Carballo, Roel and Espinola.
Conflict of interest statement
Financial support for this study was provided by Pfizer Inc. Argentina. The funder had the following involvement in the study: participated in the review and approval of the publication.
Figures
Similar articles
-
Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis.Elife. 2023 Aug 3;12:e85338. doi: 10.7554/eLife.85338. Elife. 2023. PMID: 37534878 Free PMC article.
-
Analysis of the Economic Burden of COVID-19 on the Workers of a Teaching Hospital in the Centre of Italy: Changes in Productivity Loss and Healthcare Costs Pre and Post Vaccination Campaign.Vaccines (Basel). 2023 Nov 30;11(12):1791. doi: 10.3390/vaccines11121791. Vaccines (Basel). 2023. PMID: 38140197 Free PMC article.
-
Lung cancer in Argentina: a modelling study of disease and economic burden.Public Health. 2024 Jul;232:86-92. doi: 10.1016/j.puhe.2024.03.027. Epub 2024 May 16. Public Health. 2024. PMID: 38759472
-
Economic burden of varicella in children 1-12 years of age in Argentina, 2009-2014.J Med Econ. 2018 Apr;21(4):416-424. doi: 10.1080/13696998.2018.1431919. Epub 2018 Feb 7. J Med Econ. 2018. PMID: 29357715
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
References
-
- Abr, 14. Actualización Epidemiológica: Enfermedad por coronavirus (COVID-19)—14 de abril de 2021. Available online at: https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermed... (Accessed June 25, 2023).
-
- World Health Organization (WHO). World Health Organization Scientific Brief: Multisystem Inflammatory Syndrome in Children and Adolescents with COVID-19. Geneva: WHO; (2020).
-
- Sala-ninez-adolescencia-se31.pdf.
Publication types
LinkOut - more resources
Full Text Sources